Agilent's Life Sciences Revenue Rises 30 Percent in Q4; $2B Stock Buyback Planned | GenomeWeb
NEW YORK (GenomeWeb News) - Agilent Technologies said Thursday that fiscal fourth-quarter revenues for its Bio-Analytical Measurement segment rose 24 percent, including revenues from Stratagene, which the company bought in June for around $246 million.
 
The firm’s life sciences sales were particularly strong in the quarter ended Oct. 31, rising 30 percent year over year, or 17 percent excluding Stratagene’s contribution.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.